{"name":"DongKoo Bio & Pharma","slug":"dongkoo-bio-pharma","ticker":"","exchange":"","domain":"","description":"DongKoo Bio & Pharma is a pharmaceutical company focused on developing innovative drug combinations. The company is currently in the early stages of clinical trials for its top three drugs, which include formulations of Omacor and Pritor.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pritor","genericName":"Pritor","slug":"pritor","indication":"Cerebrovascular accident","status":"phase_1"}]}],"pipeline":[{"name":"Pritor","genericName":"Pritor","slug":"pritor","phase":"phase_1","mechanism":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","indications":["Cerebrovascular accident","Disorder due to type 2 diabetes mellitus","History of myocardial infarction due to atherothrombotic coronary artery disease","Hypertensive disorder","Myocardial Infarction Prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"earnings","source":"simplywall.st","summary":"DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings Are Built On Soft Foundations - simplywall.st","headline":"DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings Are Built On Soft Foundations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9MMFV4cnBwVjEtZ1hyeE0wS0RTd0t3MXcyMUd0QVEtdHk0WEZJR1NVbmlVNS1xMWt5NVZzMXlsS1hVQWtyVnBhMGFnRTM1S1lneVI5amZmMUw0di1tdHBTU3ZyT08?oc=5","date":"2026-03-23","type":"pipeline","source":"아시아경제","summary":"Novacell, Backed by Dongkoo Bio & Pharma, Passes Technology Evaluation for KOSDAQ Listing - 아시아경제","headline":"Novacell, Backed by Dongkoo Bio & Pharma, Passes Technology Evaluation for KOSDAQ Listing - 아시아경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1rNExOSW9HQUNYMHZkQlRLbHhPOXUza3J2RlFLUURKZGNuZC02SU9vRUp0cmFxME1UblVMdWp1aFZMUl9neldncGVRWWNSZEZUMlJGX2hiUzV6dVR1NEpocjFmaFlDNGg5MXFSakNB0gFyQVVfeXFMTTUzWEJkaWM3RDJYMXhNVXpJdEJSWkY5YXBiaWdwczQyMDRRQ05sN1NnLTI0VC1tc3BWemgxbi1KdXhncHczVER2TFIwaG9VNjRpLThNS0dwSllSLXlTLTk1Mi1hN252WVV1ZDRvVGt4ejNR?oc=5","date":"2026-02-11","type":"deal","source":"koreabiomed.com","summary":"DongKoo Bio & Pharma licenses Novacell atopic dermatitis drug candidate NCP112 - koreabiomed.com","headline":"DongKoo Bio & Pharma licenses Novacell atopic dermatitis drug candidate NCP112","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB6OEM5YklvTXZTX1QzME5MMVN2cmhWSl9IMXlNWF9vRHBOM25KS0lWWG9EcGo5M2lydG5lMkVBX0JBM3dKb00xWWVsYzBOeUNGQ3B3WU1nMGw3S3dZWnZyX0ZydFVRc3hTenNMTDB30gFyQVVfeXFMT214RmVwZEpPTnZ1ZWNuejBsQW9KUm9ybi1hVElaR052RUtnUXEzWjBOTVJfbm5ieHdOSXhTNHhRTVlxSFZ0VTFyYkFvXzJYQlN2Z21ya3VVQmRpbGpqQzZGQVp5SnVCNG9Fb2h6SGZENHlR?oc=5","date":"2025-03-10","type":"pipeline","source":"koreabiomed.com","summary":"DongKoo Bio, Kukjeon to localize peptide APIs for obesity drugs, cutting reliance on imports - koreabiomed.com","headline":"DongKoo Bio, Kukjeon to localize peptide APIs for obesity drugs, cutting reliance on imports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1ORWtIc2ZmWXZodWYwY3JLMS14OTBEMDBOWC1VTFhsaU1OSEtTNUpDNEVxZmtRU3B3X1oyNk1JaGhOWm81WUVDS3g5NVZuUUgwSUkzdFF6V2NjWmg5SHhsUzN4eFJJZDZLcWF5VnZn0gFyQVVfeXFMUFlSV2dxWW5sdTFfRDNtTEhQR2p6VDZlbGVXT29vNHRCeTFjNi0yVzFUV1lDaUxKdTJwemRDM3NocXdjeERndGNaTjlTbUVTN2E4UGJKMmI3VWY3MlFzdUR0VjJ1OUFyWUt0dE5GQlhYYktR?oc=5","date":"2024-08-16","type":"pipeline","source":"koreabiomed.com","summary":"DongKoo Bio&Pharma files for injunction in appeal against GMP cancellation - koreabiomed.com","headline":"DongKoo Bio&Pharma files for injunction in appeal against GMP cancellation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5JTk5xWU5SWEpiYlRrWlFPU1FiZzFYX1hFMk4xeVZTMTY3cF9JcTdPZnozcl9NT1ZNVm9BX1FTYU1PQ1dUVElsa3hrVFpJcFRzVS1UR0UxN09lLTBub3ZNX1NBU2pCWWU3VThpclZR0gFyQVVfeXFMTmtrUDFQYmVDSzIwSjh4akZDdzhtemZXeW1lak05YjFXOFlaWlMwdlpEVTk4aE0ydWgxRjlTMVpKaGlHTHlFOG0wUHZzYUU3UkU0X0pyQzR1NGlnOXhVNy1iWkJkZGdlZFotOTlJZGkzX0hB?oc=5","date":"2024-07-26","type":"regulatory","source":"koreabiomed.com","summary":"DongKoo Bio launches erectile dysfunction-premature ejaculation combo drug - koreabiomed.com","headline":"DongKoo Bio launches erectile dysfunction-premature ejaculation combo drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1wRk55YzhJNlI5azdSTVRiZWxkeHZhX1lHQUNmWTJSTUhaakNQU0FxcXczTnNzVWFsWnNMR050bHIyYUNkR016MFpMV0NPa0FNRUw0a1o5djN6b3UyX210X0Z1dlhLSzBlRkJLVmp30gFyQVVfeXFMTjVxYV9BUG9sVzFSTmFScWpiZ2huQXVONkxwdVRvYWJFcVRJX1V2ekRpdGs3MFdaUU5ZRGhSU2t0Um56ZGdHckx0NS1MV2NnUkdRSzd2ME1kV1lPcDE1bS1uRkM3YlUyRjZRV0JsbmFEV0dB?oc=5","date":"2024-04-15","type":"pipeline","source":"koreabiomed.com","summary":"DongKoo Bio & Pharma becomes Qurient's largest shareholder through strategic investment - koreabiomed.com","headline":"DongKoo Bio & Pharma becomes Qurient's largest shareholder through strategic investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5NdUJDb0JCOGFHRHRnNHdZMFo2QThWdFhfVUw4ZWl5WlV4ZFl6MTBjZk9yYlhkX0Vhd0RtMGJTSmJkSE5DUGpER2tyeW5rc3dQQURSZ1Zsd0hGZ1BoUHpQTnBudWxIMkJxMkdXMi1B?oc=5","date":"2023-08-23","type":"pipeline","source":"KED Global","summary":"DongKoo Bio & Pharma to enter Philippine healthcare market - KED Global","headline":"DongKoo Bio & Pharma to enter Philippine healthcare market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1CSE54THdZS0VJVmVpcnV0cnc2bzNRQnB2MFpSQk1jZlJTeFg3dmtJRlZzSENyQkNMd0Q3bUV2WnJ5UUdVMElJUFlTLXhnVDY1SDJRV295T09aYXZ4QVNTMml5WUZSRTk5S2xOaVJ30gFyQVVfeXFMT1BrMWZSVmlQYl84eXRfMUFFSGx2bExIamZMWFhKNDZITUYyR2dESmE3N1NTbUhUY3ZVSUNWMWtmZ3l5aEFJLURpNlpPano4NC1NR3czX3NGaHFPQ3NIc2lCVFV5Sjg1dlJ5ZkduQVZ4VUpR?oc=5","date":"2022-12-28","type":"regulatory","source":"koreabiomed.com","summary":"Only 1 patent barrier remains for launch of Amgen's Otezla generics in Korea - koreabiomed.com","headline":"Only 1 patent barrier remains for launch of Amgen's Otezla generics in Korea","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}